Safety comparison of high-dose methotrexate via different intravenous infusion devices in pediatric patients with malignant brain tumors

XU Xiqiao; SHI Zhengyuan; YANG Chunjing; WANG Shumei

doi:10.6039/j.issn.1001-0408.2023.07.14

您当前的位置：

首页 >

文章列表页 >

Safety comparison of high-dose methotrexate via different intravenous infusion devices in pediatric patients with malignant brain tumors

更新时间：2024-02-19

- Safety comparison of high-dose methotrexate via different intravenous infusion devices in pediatric patients with malignant brain tumors
- ZHONGGUO YAOFANG Vol. 34, Issue 7, Pages: 844-848(2023)
- 作者机构：
  
  首都医科大学附属北京世纪坛医院药学部/临床合理用药生物特征谱学评价北京市重点实验室，北京　100038
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.07.14
  CLC： R969.3;R979.1
- Published：15 April 2023，
  
  Received：09 October 2022，
  
  Revised：27 March 2023，
扫描看全文
续茜桥,时正媛,杨春静等.经不同静脉输液装置给予颅内恶性肿瘤患儿大剂量甲氨蝶呤的安全性比较 ^Δ[J].中国药房,2023,34(07):844-848.

XU Xiqiao,SHI Zhengyuan,YANG Chunjing,et al.Safety comparison of high-dose methotrexate via different intravenous infusion devices in pediatric patients with malignant brain tumors[J].ZHONGGUO YAOFANG,2023,34(07):844-848.
续茜桥,时正媛,杨春静等.经不同静脉输液装置给予颅内恶性肿瘤患儿大剂量甲氨蝶呤的安全性比较 ^Δ[J].中国药房,2023,34(07):844-848. DOI： 10.6039/j.issn.1001-0408.2023.07.14.

XU Xiqiao,SHI Zhengyuan,YANG Chunjing,et al.Safety comparison of high-dose methotrexate via different intravenous infusion devices in pediatric patients with malignant brain tumors[J].ZHONGGUO YAOFANG,2023,34(07):844-848. DOI： 10.6039/j.issn.1001-0408.2023.07.14.

摘要

目的

比较颅内恶性肿瘤患儿经外周穿刺中心静脉导管（PICC）与植入式静脉输液港（TIVAP）给予大剂量甲氨蝶呤（HD-MTX）的安全性。

方法

回顾性分析本院2018年7月至2022年4月经PICC或TIVAP给予HD-MTX的颅内恶性肿瘤患儿病例，收集临床资料，比较两组患儿甲氨蝶呤（MTX）血药浓度、不良事件（包括药物不良反应和导管相关并发症）发生率及住院天数差异。应用多因素线性回归分析MTX血药浓度的影响因素。

结果

共纳入病例107例，其中PICC组65例、TIVAP组42例。TIVAP组给药后24 h MTX血药浓度（

24 h

水平）显著高于PICC组[（126.87±61.99） μmol/L vs. （102.45±48.77） μmol/L，

＜0.05]，给药后42 h MTX血药浓度（

42 h

水平）与PICC组比较差异无统计学意义（

＞0.05）。多因素线性回归分析结果显示，经TIVAP给药与MTX

24 h

水平升高有关（

＜0.05）。两组间不良事件发生率与住院天数的差异均无统计学意义（

＞0.05）。

结论

经TIVAP给药可能出现MTX

24 h

水平升高，但不会提高不良事件发生率。在实施治疗药物监测的情况下，经TIVAP给予HD-MTX是较为安全的选择。

Abstract

OBJECTIVE

To compare the safety of high-dose methotrexate （HD-MTX） via peripherally inserted central catheter （PICC） and totally implantable venous access port （TIVAP） in pediatric patients with malignant brain tumors.

METHODS

Patients with malignant brain tumors who received HD-MTX via PICCs or TIVAPs in our hospital from July 2018 to April 2022 were retrospectively analyzed. Clinical data were collected to compare differences in blood concentration of methotrexate （MTX），the incidence of adverse events （including adverse drug reactions and catheter-related complications） and length of stay in hospital. Multivariate linear regression was applied to analyze the factors that influenced the blood concentration of MTX.

RESULTS

A total of 107 patients were included in the study，with 65 patients in the PICC group and 42 patients in the TIVAP group. Blood concentration of MTX at 24 h （

24 h

） in TIVAP group was significantly higher than PICC group [（126.87±61.99） μmol/L vs. （102.45±48.77） μmol/L，

＜0.05）. There was no significant difference in blood concentration of MTX at 42 h （

42 h

），compared with PICC group （

＞0.05）. Results of multivariate linear regression analysis showed that TIVAP was associated with the increase of

24 h

（

＜0.05）. No significant differences were observed in the incidence of adverse events and the length of stay in the hospital between 2 groups （

＞0.05）.

CONCLUSIONS

Risk of adverse events is not increased，although the MTX

24 h

level is elevated after administration of TIVAP. TIVAP is a safe choice for HD-MTX therapy with implementing therapeutic drug monitoring.

关键词

甲氨蝶呤植入式静脉输液港外周穿刺中心静脉导管颅内恶性肿瘤治疗药物监测血药浓度不良事件

Keywords

totally implantable venous access portperipherally inserted central cathetermalignant brain tumortherapeutic drug monitoringblood concentrationadverse event

references

唐慧，郭鸿，曹芳，等. 2005－2015年中国0～14岁儿童恶性肿瘤流行特征研究[J]. 中国全科医学，2022，25（8）：984-989，1006.

MIELKE D，WITTIG A，TEICHGRÄBER U. Periphe- rally inserted central venous catheter （PICC） in outpatient and inpatient oncological treatment[J]. Support Care Cancer，2020，28（10）：4753-4760.

HERD F，MILLER T，VAN DELFT F W，et al. The peripheral portacath provides safe and convenient venous access in pediatric and adolescent patients[J]. J Pediatr Surg，2019，54（7）：1449-1452.

QI H J，YANG W W，ZHANG L D，et al. Peripherally inserted central catheters for calcium requirements after successful parathyroidectomy：a comparison with centrally inserted catheters[J]. Ann R Coll Surg Engl，2017，99（5）：358-362.

SONG Z W，HU Y，LIU S，et al. Medication therapy of high-dose methotrexate：an evidence-based practice guideline of the Division of Therapeutic Drug Monitoring，Chinese Pharmacological Society[J]. Br J Clin Pharmacol，2022，88（5）：2456-2472.

王卫平，孙锟，常立文. 儿科学[M]. 9版. 北京：人民卫生出版社，2018：41-42.

SCHWARTZ G J，MUÑOZ A，SCHNEIDER M F，et al. New equations to estimate GFR in children with CKD[J]. J Am Soc Nephrol，2009，20（3）：629-637.

WRIGHT K D，PANETTA J C，ONAR-THOMAS A，et al. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections[J]. Cancer Chemother Pharmacol，2015，75（1）：27-35.

ZHANG H，LI Y M，ZHU N N，et al. Comparison of peripherally inserted central catheters （PICCs） versus totally implantable venous-access ports in pediatric onco- logy patients，a single center study[J]. Sci Rep，2022，12（1）：3510.

PATEL N，PETERSEN T L，SIMPSON P M，et al. Rates of venous thromboembolism and central line-associated bloodstream infections among types of central venous access devices in critically ill children[J]. Crit Care Med，2020，48（9）：1340-1348.

孙丽，任玲，安琪，等. 某三甲儿童医院甲氨蝶呤血药浓度监测及影响因素分析[J]. 儿科药学杂志，2019，25（2）：44-46.

时正媛，续茜桥，杨春静，等. 髓母细胞瘤患儿甲氨蝶呤的血药浓度与肾功能的相关性研究[J]. 中国新药杂志，2021，30（8）：701-704.

张春燕，任晓蕾，冯婉玉，等. MTHFR和ABCB1基因多态性对大剂量甲氨蝶呤毒性反应及排泄延迟的影响[J]. 中国新药杂志，2019，28（1）：117-120.

邹羽真，梅丹，付强，等. 1 050例大剂量甲氨蝶呤合并用药探索并典型病例分析[J]. 中国医院药学杂志，2018，38（15）：1624-1628.

WRIGHT D F，AL-SALLAMI H S，JACKSON P M，et al. Falsely elevated vancomycin plasma concentrations sampled from central venous implantable catheters （portacaths）[J]. Br J Clin Pharmacol，2010，70（5）：769-772.

GIJSEN M，MAERTENS J，LAGROU K，et al. Cefepime therapeutic drug monitoring：evaluation of agreement between peripheral and central venous blood sampling[J]. Clin Chim Acta，2020，510：450-454.

宋再伟，黄振城，张恩瑶，等. 血液肿瘤患者大剂量甲氨蝶呤输注24h时血药浓度与临床结局相关性的meta分析[J]. 药物不良反应杂志，2019，21（3）：183-189.

王倩，马赛男，蔡炜嵩. 儿童骨肉瘤应用大剂量甲氨蝶呤化疗后肝肾功能损伤及排泄延迟分析[J]. 国际儿科学杂志，2018，45（7）：565-567.

RYAN C，HESSELGREAVES H，WU O，et al. Patient acceptability of three different central venous access devices for the delivery of systemic anticancer therapy：a qualitative study[J]. BMJ Open，2019，9（7）：e026077.

PATERSON R S，CHOPRA V，BROWN E，et al. Selection and insertion of vascular access devices in pediatrics：a systematic review[J]. Pediatrics，2020，145（Suppl 3）：S243-S268.

李晨晨，胡明，褚珺，等. 外周穿刺中心静脉导管与完全植入式静脉输液港在儿童肿瘤的临床比较[J]. 介入放射学杂志，2018，27（8）：735-739.

LEE J K，CHOI Y B. Incidence and risk factors for totally implantable venous access device infections in pediatric patients with cancer：a study of 25 954 device-days[J]. J Korean Med Sci，2022，37（35）：e266.

中心静脉通路上海协作组，上海市抗癌协会实体肿瘤聚焦诊疗专委会血管通路专家委员会. 完全植入式输液港上海专家共识：2019[J]. 介入放射学杂志，2019，28（12）：1123-1128.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Signal mining and analysis of adverse events of oseltamivir， zanamivir and baloxavir marboxil

Excavation and evaluation of adverse reaction signals of 4 kinds of imported PD- 1/PD-L1 inhibitors

Data-mining of Adverse Drug Events Signals for Tocilizumab Based on US FAERS Database

ADR Signal Mining of Paclitaxel for Injection （Albumin-bound Type ）Based on FDA Adverse Event Database

Data Analysis of the Risks of Abnormal Female Reproductive System Haemorrhages Induced by Novel Oral An- ticoagulants Based on FAERS

Related Author

LIU Yao

LI Yanping

SU Hui

ZHANG Ni

JIANG Tingting

YU Xian

LI Guoxing

SHU Jiahua

Related Institution

Department of Pharmacy， Daping Hospital， Army Medical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰